The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy

被引：8
作者：
Boretti, Alberto [1 ]
机构：
[1] Independent Scientist, Wellington
来源：
Computers in Biology and Medicine | 2024年 / 182卷
关键词：
AI-Driven; CAR T-cell therapy; CRISPR-Cas9; Genome editing; Inhibitory effects; Manufacturing costs; Personalized immunotherapy; Precise targeting; Safety;
D O I：
10.1016/j.compbiomed.2024.109137
中图分类号：
学科分类号：
摘要：
This narrative review examines the promising potential of integrating artificial intelligence (AI) with CRISPR-Cas9 genome editing to advance CAR T-cell therapy. AI algorithms offer unparalleled precision in identifying genetic targets, essential for enhancing the therapeutic efficacy of CAR T-cell treatments. This precision is critical for eliminating negative regulatory elements that undermine therapy effectiveness. Additionally, AI streamlines the manufacturing process, significantly reducing costs and increasing accessibility, thereby encouraging further research and development investment. A key benefit of AI integration is improved safety; by predicting and minimizing off-target effects, AI enhances the specificity of CRISPR-Cas9 edits, contributing to safer CAR T-cell therapy. This advancement is crucial for patient safety and broader clinical adoption. The convergence of AI and CRISPR-Cas9 has transformative potential, poised to revolutionize personalized immunotherapy. These innovations could expand the application of CAR T-cell therapy beyond hematologic malignancies to various solid tumors and other non-hematologic conditions, heralding a new era in cancer treatment that substantially improves patient outcomes. © 2024 Elsevier Ltd
引用
收藏
相关论文
共 66 条
[1]  
Sterner R.C., Sterner R.M., CAR-T cell therapy: current limitations and potential strategies, Blood Cancer J., 11, 4, (2021)
[2]  
Rafiq S., Hackett C.S., Brentjens R.J., Engineering strategies to overcome the current roadblocks in CAR T cell therapy, Nat. Rev. Clin. Oncol., 17, 3, pp. 147-167, (2020)
[3]  
Bonifant C.L., Jackson H.J., Brentjens R.J., Curran K.J., Toxicity and management in CAR T-cell therapy, Molecular Therapy-Oncolytics, 3, (2016)
[4]  
Newick K., O'Brien S., Moon E., Albelda S.M., CAR T cell therapy for solid tumors, Annu. Rev. Med., 68, pp. 139-152, (2017)
[5]  
Maakaron J.E., Hu M., El Jurdi N., Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations, BMJ, 378, (2022)
[6]  
Carroll D., Genome engineering with zinc-finger nucleases, Genetics, 188, 4, pp. 773-782, (2011)
[7]  
Sun N., Zhao H., Transcription activator‐like effector nucleases (TALENs): a highly efficient and versatile tool for genome editing, Biotechnol. Bioeng., 110, 7, pp. 1811-1821, (2013)
[8]  
Silva G., Poirot L., Galetto R., Smith J., Montoya G., Duchateau P., Paques F., Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy, Curr. Gene Ther., 11, 1, pp. 11-27, (2011)
[9]  
Redman M., King A., Watson C., King D., What is CRISPR/Cas9?, Arch. Dis. Child. Educ. Pract., 101, 4, pp. 213-215, (2016)
[10]  
Doudna J.A., Charpentier E., The new frontier of genome engineering with CRISPR-Cas9, Science, 346, 6213, (2014)
1234567